Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

901. Verapamil use in patients with cardiovascular disease: an overview of randomized trials

Verapamil use in patients with cardiovascular disease: an overview of randomized trials Verapamil use in patients with cardiovascular disease: an overview of randomized trials Verapamil use in patients with cardiovascular disease: an overview of randomized trials Pepine C J, Faich G, Makuch R Authors' objectives To present an overview of randomised trials investigating the use of verapamil in patients with cardiovascular disease. Searching MEDLINE was searched from January 1966 to April 1997 (...) conclusions. These findings support the need to distinguish between different calcium-antagonist compounds, and emphasise the need for more data in patients with hypertension. CRD commentary This review used clearly defined inclusion criteria for study design and outcome assessment, to investigate the use of verapamil in cardiovascular disease. A clearly outlined search strategy was used to locate relevant information, and the terms used in the retrieval were listed to enable other researchers to repeat

1998 DARE.

902. Cost-effectiveness of primary and secondary prevention in cardiovascular diseases

Cost-effectiveness of primary and secondary prevention in cardiovascular diseases Cost-effectiveness of primary and secondary prevention in cardiovascular diseases Cost-effectiveness of primary and secondary prevention in cardiovascular diseases Troche C J, Tacke J, Hinzpeter B, Danner M, Lauterbach K W Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Prevention programmes for cardiovascular diseases. Type of intervention Primary prevention and secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population was a hypothetical population of 1,000 men aged 45-64 years with plasma cholesterol levels of 7+ Setting Primary care. The study was carried out in Germany. Dates to which

1998 NHS Economic Evaluation Database.

903. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. (Abstract)

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. Inflammation may be important in the pathogenesis of atherothrombosis. We studied whether inflammation increases the risk of a first thrombotic event and whether treatment with aspirin decreases the risk.We measured plasma C-reactive protein, a marker for systemic inflammation, in 543 apparently healthy men participating in the Physicians' Health Study in whom myocardial infarction, stroke, or venous (...) -reactive protein, raising the possibility that antiinflammatory agents may have clinical benefits in preventing cardiovascular disease.

1997 NEJM Controlled trial quality: uncertain

904. Aspirin in the primary prevention of cardiovascular disease and colon cancer

cancer. ASA prophylaxis is effective in various groups who are at high risk for cardiovascular disease. However, more effective treatments are available for some conditions, such as atrial fibrillation, which are associated with a high risk of stroke, though such treatments are associated with a higher risk of complications. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Aspirin /therapeutic use; Cerebrovascular Disorders; Colorectal Neoplasms; Myocardial Infarction (...) Aspirin in the primary prevention of cardiovascular disease and colon cancer Aspirin in the primary prevention of cardiovascular disease and colon cancer Aspirin in the primary prevention of cardiovascular disease and colon cancer Hailey D, Harstall C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Hailey D, Harstall C. Aspirin

1997 Health Technology Assessment (HTA) Database.

905. Is there a role for antioxidant vitamins in the prevention of cardiovascular diseases: an update on epidemiological and clinical trials data

Is there a role for antioxidant vitamins in the prevention of cardiovascular diseases: an update on epidemiological and clinical trials data Is there a role for antioxidant vitamins in the prevention of cardiovascular diseases: an update on epidemiological and clinical trials data Is there a role for antioxidant vitamins in the prevention of cardiovascular diseases: an update on epidemiological and clinical trials data Lonn E M, Yusuf S Authors' objectives To review prospective epidemiological (...) studies and randomised clinical trials regarding the role of antioxidant vitamins (vitamins E and C and beta-carotene) in the prevention of cardiovascular diseases. Searching MEDLINE and the Science Citation Index were searched (dates and search terms were not stated). Manual searches on the role of antioxidant vitamins in cardiovascular disease management were also carried out (no further details were given). Study selection Study designs of evaluations included in the review Prospective

1997 DARE.

906. School-based cardiovascular disease prevention studies: review and synthesis

School-based cardiovascular disease prevention studies: review and synthesis School-based cardiovascular disease prevention studies: review and synthesis School-based cardiovascular disease prevention studies: review and synthesis Resnicow K, Robinson T N Authors' objectives To evaluate the effectiveness of school-based cardiovascular disease (CVD) prevention programmes. Searching The authors searched MEDLINE (using both MeSH terms and textwords), bibliographies of published studies, archives (...) . School-based cardiovascular disease prevention studies: review and synthesis. Annals of Epidemiology 1997; 7(7 Supplement): S14-S31 Indexing Status Subject indexing assigned by CRD MeSH Adolescent; Cardiovascular Diseases /prevention & Child; Health Education; Health Promotion; control AccessionNumber 11997001379 Date bibliographic record published 31/10/2000 Date abstract record published 31/10/2000 Record Status This is a critical abstract of a systematic review that meets the criteria

1997 DARE.

907. A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients

A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients (...) the clinical study were made (although few were known to exist), with the differences in results being explained by the authors mostly in terms of the differences involved in the scope of the clinical endpoints selected. Source of funding None stated. Bibliographic details Milne R J, Hoorn S V, Jackson R T. A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients. PharmacoEconomics 1997; 12(3): 384

1997 NHS Economic Evaluation Database.

908. Community intervention programs to prevent cardiovascular disease</a>

Community intervention programs to prevent cardiovascular disease Community intervention programs to prevent cardiovascular disease We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Community intervention programs to prevent cardiovascular disease Share: Reading time approx. 2 minutes This document was published more than 2 years ago. The nature (...) of the evidence may have changed. Purpose The primary purpose of this investigation is to: systematically review, compile, and assess community intervention programs aimed at preventing cardiovascular diseases, describe and analyze trends concerning the occurrence and progression of cardiovascular diseases in Sweden, develop recommendations on community intervention programs for decision makers and staff involved with public health issues. Methods Systematic review of the literature and cost analysis

1997 Swedish Council on Technology Assessement

909. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. Full Text available with Trip Pro

Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. Observational studies suggest that people who consume more fruits and vegetables containing beta carotene have somewhat lower risks of cancer and cardiovascular disease, and earlier basic research suggested plausible mechanisms. Because large randomized trials of long duration were necessary to test this hypothesis directly, we conducted a trial of beta carotene (...) assigned to receive beta carotene and 11,035 assigned to receive placebo, there were virtually no early or late differences in the overall incidence of malignant neoplasms or cardiovascular disease, or in overall mortality. In the beta carotene group, 1273 men had any malignant neoplasm (except nonmelanoma skin cancer), as compared with 1293 in the placebo group (relative risk, 0.98; 95 percent confidence interval, 0.91 to 1.06). There were also no significant differences in the number of cases of lung

1996 NEJM Controlled trial quality: predicted high

910. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. Full Text available with Trip Pro

Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. Lung cancer and cardiovascular disease are major causes of death in the United States. It has been proposed that carotenoids and retinoids are agents that may prevent these disorders.We conducted a multicenter, randomized, double-blind, placebo-controlled primary prevention trial -- the Beta Carotene and Retinol Efficacy Trial -- involving a total of 18,314 smokers, former smokers, and workers (...) to 1.57; P=0.02), as compared with the placebo group. There were no statistically significant differences in the risks of other types of cancer. In the active-treatment group, the relative risk of death from any cause was 1.17 (95 percent confidence interval, 1.03 to 1.33); of death from lung cancer, 1.46 (95 percent confidence interval, 1.07 to 2.00); and of death from cardiovascular disease, 1.26 (95 percent confidence interval, 0.99 to 1.61). On the basis of these findings, the randomized trial

1996 NEJM Controlled trial quality: predicted high

911. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. (Abstract)

Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. To assess the effect of low-dose, diuretic-based antihypertensive treatment on major cardiovascular disease (CVD) event rates in older, non-insulin-treated diabetic patients with isolated systolic hypertension (ISH), compared with nondiabetic patients.Double-blind, randomized (...) , nonfatal plus fatal stroke, nonfatal myocardial infarction (MI) and fatal coronary heart disease (CHD), major CHD events, and all-cause mortality.The SHEP antihypertensive drug regimen lowered BP of both diabetic and nondiabetic patients, with few adverse effects. For both diabetic and nondiabetic patients, all outcome rates were lower for participants randomized to the active treatment group than for those randomized to the placebo group. Thus, 5-year major CVD rate was lower by 34% for active

1996 JAMA Controlled trial quality: predicted high

912. Ethnicity and health: reviews of literature and guidance for purchasers in the areas of cardiovascular disease, mental health and haemoglobinopathies

Ethnicity and health: reviews of literature and guidance for purchasers in the areas of cardiovascular disease, mental health and haemoglobinopathies Ethnicity and health: reviews of literature and guidance for purchasers in the areas of cardiovascular disease, mental health and haemoglobinopathies Ethnicity and health: reviews of literature and guidance for purchasers in the areas of cardiovascular disease, mental health and haemoglobinopathies NHS Centre for Reviews and Dissemination; Social (...) Policy Research Unit, University of York Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHS Centre for Reviews and Dissemination; Social Policy Research Unit, University of York. Ethnicity and health: reviews of literature and guidance for purchasers in the areas of cardiovascular disease, mental health and haemoglobinopathies. University

1996 Health Technology Assessment (HTA) Database.

913. Bleeding risk of combined oral anticoagulant and antiplatelet therapy in cardiovascular disease

Bleeding risk of combined oral anticoagulant and antiplatelet therapy in cardiovascular disease Bleeding risk of combined oral anticoagulant and antiplatelet therapy in cardiovascular disease Bleeding risk of combined oral anticoagulant and antiplatelet therapy in cardiovascular disease Verheugt F W Authors' objectives To assess the safety of combining oral anticoagulant and antiplatelet therapy. Searching EMBASE was searched from 1960 to 1994. [A: The search strategy was not defined. Only (...) studies made? The author does not state how the papers were selected for the review, or how many of the reviewers performed the selection. Assessment of study quality [A: All studies which combined oral anticoaguant and antiplatelet therapy were included, provided cardiovascular disorders were treated]. The author does not state how the papers were assessed for validity, or how many of the reviewers performed the validity assessment. Data extraction The author does not state how the data were

1996 DARE.

914. Cost effectiveness and equity of a community based cardiovascular disease prevention programme in Norsjo, Sweden

Cost effectiveness and equity of a community based cardiovascular disease prevention programme in Norsjo, Sweden Cost effectiveness and equity of a community based cardiovascular disease prevention programme in Norsjo, Sweden Cost effectiveness and equity of a community based cardiovascular disease prevention programme in Norsjo, Sweden Lindholm L, Rosen M, Weinehall L, Asplund K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Community based cardiovascular disease prevention (educational) programme. Type of intervention Screening; Primary prevention; Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population was taken from a rural community in Northern Sweden with an 80

1996 NHS Economic Evaluation Database.

915. Cardiovascular disease. (Abstract)

Cardiovascular disease. The Thrombolysis in Myocardial Ischemia trial randomized patients with unstable angina or non-Q-wave myocardial infarction and found that thrombolytic therapy was not beneficial and may be harmful. Drug treatment of hypercholesterolemia improves survival in patients with established coronary artery disease.

1995 JAMA

916. The antioxidant vitamins and cardiovascular disease: a critical review of epidemiologic and clinical trial data

The antioxidant vitamins and cardiovascular disease: a critical review of epidemiologic and clinical trial data The antioxidant vitamins and cardiovascular disease: a critical review of epidemiologic and clinical trial data The antioxidant vitamins and cardiovascular disease: a critical review of epidemiologic and clinical trial data Jha P, Flather M, Lonn E, Farkouh M, Yusuf S Authors' objectives To review prospective epidemiological studies and randomised trials regarding the role (...) of antioxidant vitamins (vitamins E and C, and beta-carotene) in the prevention of cardiovascular disease. Searching Scientific literature was searched for all epidemiological studies (prospective cohort, prospective nested case-control, retrospective case-control, or geographic correlations) and RCTs of antioxidants and cardiovascular disease. Keywords used were 'vitamin E', 'vitamin C', 'beta-carotene', 'vitamins', 'antioxidants', 'coronary heart disease', 'cerebrovascular disease', 'peripheral vascular

1995 DARE.

917. Long-term mortality after 5-year multifactorial primary prevention of cardiovascular diseases in middle-aged men. (Abstract)

Long-term mortality after 5-year multifactorial primary prevention of cardiovascular diseases in middle-aged men. To investigate the long-term effects of multifactorial primary prevention of cardiovascular diseases (CVD).The 5-year randomized, controlled trial was performed between 1974 and 1980. The subjects and their risk factors were reevaluated in 1985. Posttrial mortality follow-up was continued up to December 31, 1989.Institute of Occupational Health, Helsinki, Finland, and Second (...) . Multiple logistic regression analysis of treatments in the intervention group did not explain the 15-year excess cardiac mortality.These unexpected results may not question multifactorial prevention as such but do support the need for research on the selection and interaction(s) of methods used in the primary prevention of cardiovascular diseases.

1991 JAMA Controlled trial quality: predicted high

918. Cardiovascular disease risk reduction for tenth graders. A multiple-factor school-based approach. (Abstract)

Cardiovascular disease risk reduction for tenth graders. A multiple-factor school-based approach. All tenth graders in four senior high schools (N = 1447) from two school districts participated in a cardiovascular disease risk-reduction trial. Within each district, one school was assigned at random to receive a special 20-session risk-reduction intervention and one school served as a control. At a two-month follow-up, risk factor knowledge scores were significantly greater for students (...) choose "heart-healthy" snack items. Beneficial treatment effects were observed for resting heart rate, body mass index, triceps skin fold thickness, and subscapular skin fold thickness. The results suggest that it is feasible to provide cardiovascular disease risk-reduction training to a large segment of the population through school-based primary prevention approaches.

1988 JAMA Controlled trial quality: uncertain

919. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. (Abstract)

Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Results of the European Working Party on High Blood Pressure in the Elderly (EWPHE) trial have been analysed in relation to age, sex, blood pressure, and previous cardiovascular disease. Cardiovascular mortality and the cardiovascular study-terminating events were significantly and independently related to treatment, age, cardiovascular (...) complications at randomisation, and systolic but not diastolic blood pressure. The benefits of treatment observed in the trial seemed to be independent of entry blood pressure and the presence or absence of cardiovascular complications at entry. There was some evidence that treatment effect decreases with advancing age. Little or no benefit from treatment could be demonstrated in patients over the age of 80 years, the great majority of whom were women.

1986 Lancet Controlled trial quality: uncertain

920. Multifactorial primary prevention of cardiovascular diseases in middle-aged men. Risk factor changes, incidence, and mortality. (Abstract)

Multifactorial primary prevention of cardiovascular diseases in middle-aged men. Risk factor changes, incidence, and mortality. In a randomized five-year multifactorial primary prevention trial of vascular diseases, hyperlipidemias, hypertension, smoking, obesity, and abnormal glucose tolerance of the high-risk test group (n = 612 men) were treated with dietetic-hygienic measures and hypolipidemic (mainly probucol and clofibrate) and antihypertensive (mainly diuretics and beta-blockers) agents

1985 JAMA Controlled trial quality: uncertain